Clinical effects of ghrelin on gastrointestinal involvement in patients with systemic sclerosis

Clinical effects of ghrelin on gastrointestinal involvement in patients with systemic sclerosis - Clinical effects of ghrelin on GI involvement in SSc

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003739

Enrollment

Registered

2010-09-01

Start date

2010-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

systemic sclerosis

Interventions

Treatment A-2 wks after-Treatment B Treatment B-2 wks after-Treatment A

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Dx as SSc 2) Gastrointestinal involvement (+) 3) Informed consent (+)

Exclusion criteria

Exclusion criteria: 1) localized scleroderma 2) dysphagia due to the stenosis of esophagus 3) Intravenous Hyperalimentation or tube feeding 4) past history of open-abdominal operation of GI tract 5) allergy against milk or Lacol 6) Severe hepato-renal or respiratory disorders, severe depression, schizophrenia, mania, severe diabetes, congenital amino acid metabolic disorder 7)tendency or past history of suicide

Design outcomes

Primary

Measure	Time frame
Tmax in 13C respiration test	—

Countries

Japan

Contacts

Public ContactTakashi Akamizu

Kyoto University Hospital Translational research center

akamizu@kuhp.kyoto-u.ac.jp075-751-4720

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026